Bausch Health Companies Stock: 5 Straight Green Days, Up 56%
A streak in Bausch Health stock has investors watching, but the underlying numbers offer a different kind of story.
Bausch Health Companies (BHC) stock has moved higher for 5 consecutive trading days, delivering a cumulative gain of 56%. That streak has added about $923 million to the company’s market value, which now stands at about $2.6 billion. For anyone holding the shares, this represents a significant and rapid revaluation.
How The Streak Stacks Up Against The S&P 500
Here is how BHC stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | BHC | S&P 500 |
|---|---|---|
| 1D | 14.3% | 0.7% |
| 5D (Current Streak) | 55.5% | 1.0% |
| 1M (21D) | 44.4% | 0.1% |
| 3M (63D) | 20.5% | 3.9% |
| YTD 2026 | -0.9% | 9.4% |
| 2025 | -13.8% | 16.4% |
| 2024 | 0.5% | 23.3% |
| 2023 | 27.7% | 24.2% |
Does the business performance justify this move?
The data suggests the market may be weighing some genuine operational strengths. BHC’s revenue over the last twelve months grew 10.1%, ahead of the S&P 500 median revenue growth of 7.8%. Its operating margin of 25.4% also stands above the 18.4% median for the index. While the company has negative trailing earnings, its free cash flow yield is 53.9%.
This run is also specific to the company, a move independent of a general market lift. Over the same 5 trading days, the S&P 500 returned just +1.0%. Further, such winning streaks are not common at the moment: only 18 S&P 500 stocks are on winning streaks of 3 days or more, while 88 are on losing streaks.
What is the right way to react to a streak?
A streak is information, not an instruction. It tells you that a stock has captured the market’s attention and has strong near-term momentum. It is not, by itself, a signal to buy or sell. The disciplined response is to use the new price as a prompt to re-evaluate the underlying business. The fundamental metrics here provide a starting point for that work: checking if the current valuation aligns with the company’s performance.
A run like this is worth respecting, and worth testing: the momentum that lasts is usually the kind management itself is underwriting. Our Guidance Momentum screen tracks the stocks whose companies just raised their own forward numbers.
Prefer the theme to this single name? A healthcare ETF like XLV owns the whole group. That way no single company’s next surprise decides the outcome.
Winning Streaks Are How Portfolios Get Concentrated
A stock that rises day after day quietly becomes a bigger share of the portfolio holding it. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.